Economic return of clinical trials performed under the pediatric exclusivity program

JAMA

Volumn 297, Issue 5, 2007, Pages 480-488

  Li, Jennifer S ^a,b,d   Eisenstein, Eric L ^b   Grabowski, Henry G ^c   Reid, Elizabeth D ^b   Mangum, Barry ^b   Schulman, Kevin A ^b   Goldsmith, John V ^d   Murphy, M Dianne ^d   Califf, Robert M ^b   Benjamin, Daniel K ^a,b,d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANXIOLYTIC AGENT; NEUROLEPTIC AGENT;

ARTICLE; ASTHMA; ATTENTION DEFICIT DISORDER; BACTERIAL INFECTION; BONE MINERALIZATION; CHILD HEALTH CARE; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DEPRESSION; DIABETES MELLITUS; DRUG COST; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC EVALUATION; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; GENERALIZED ANXIETY DISORDER; HEALTH PROGRAM; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TAX; TUMOR;

EID: 33846878293     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.5.480     Document Type: Article

References (25)

1. Wilson JT. An update on the therapeutic orphan. Pediatrics. 1999;104:585-590.
2. Benjamin DK Jr, Smith PB, Murphy MD, et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA. 2006;296:1266-1273.
3. US General Accounting Office. Testimony before the Committee on Health, Education, Labor, and Pensions, US Senate. Pediatric drug research: substantial increase in studies of drugs for some children but challenges remains. GAO-01-705 T. http://www.gao.gov/new.items/d01705t.pdf. Accessibility verified January 5, 2007.
4. Specific Requirements on Content and Format of Labeling for Human Prescription Drugs: Revision of "Pediatric Use" Subsection of Labeling. 59 Federal Register 64242 (1994).
5. US Food and Drug Administration Modernization Act of 1997, Pub L No. 105-115, 111 Stat 2296 (1997).
6. Best Pharmaceuticals for Children Act of 2002, Pub L No. 107-109 (2002).
7. Public Citizen. Patently offensive: Congress set to extend monopoly patents for Cipro and other drugs. November 9, 2001. http://www.citizen.org/ congress/reform/drug_patents/pediatric/articles.cfm?ID=6435. Accessibility verified January 5, 2007.
8. Milne CP. The Pediatric Studies Incentive: Equal Medicines for All. Boston, Mass: Tufts University; 2001.
9. US Food and Drug Administration. Summaries of medical and clinical pharmacology reviews of pediatric studies as of January 3, 2007. http://www.fda.gov/cder/pediatric/Summaryreview.htm. Accessibility verified January 5, 2007.
10. Fast Track Systems Clinical Trial Software home page. http://www.fast-track.com. Accessibility verified January 5, 2007.
11. Covance home page. http://www.covance.com. Accessibility verified January 5, 2007.
12. Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics. 2002;20(suppl 3):11-29.
13. IMS Health home page. http://www.imshealth.com. Accessibility verified January 5, 2007.
14. Finkler SA. Alternative contribution margin measures. In: Finkler SA, ed. Issues in Cost Accounting for Health Care Organizations. Gaithersburg, Md: Aspen Publishers; 1994:124-127.
15. Li JS, Berezny K, Kilaru R, et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension. 2004;44:289-293.
16. Flynn JT, Newburger JW, Daniels SR, et al; PATH-1 Investigators. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145:353-359.
17. Benjamin DK Jr, Driscoll T, Siebel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. 2006;50:632-638.
18. Benjamin DK Jr, Schelonka R, White R, et al; the S. aureus Prevention Investigators. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol. 2006;26:290-295.
19. Kesselheim AS, Avorn J. Biomedical patents and the public's health: is there a role for eminent domain? JAMA. 2006;295:434-436.
20. Barton JH, Emanuel EJ. The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA. 2005;294:2075-2082.
21. Kaitin KI, ed. US Pediatric Studies Incentive Led to New Labeling for Nearly 100 Drugs. Boston, Mass: Tufts University; 2005.
22. Newman TB. A black-box warning for antidepressants in children? N Engl J Med. 2004;351:1595-1598.
23. Brent DA. Antidepressants and pediatric depression - the risk of doing nothing. N Engl J Med. 2004;351:1598-1601.
24. Hampton T. Suicide caution stamped on antidepressants. JAMA. 2004;291:2060-2061.
25. US Food and Drug Administration. Pediatric Exclusivity Labeling Changes as of November 22, 2006. http://www.fda.gov/cder/pediatric/labelchange.htm. Accessibility verified January 5, 2007.